Appropriate timing of G-CSF use after mobilization chemotherapy significantly increases the yield of CD34+ cells in autoPBSCT

Journal of Clinical Apheresis

Volumn 24, Issue 6, 2009, Pages 232-237

  Xu, Li ^a   Chang, Chunkang ^a   Li, Xiao ^a   Gan, Weijin ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b NEW YORK UNIVERSITY CHILD STUDY CENTER   (United States)

Author keywords

Autologous peripheral blood stem cell transplantation; G CSF; Mobilization; Timing

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CD34 SELECTION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LEUKAPHERESIS; LEUKOCYTE COUNT; LYMPHOMA; MALE; MONONUCLEAR CELL; MULTIPLE MYELOMA; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; TREATMENT DURATION;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKAPHERESIS; LEUKOCYTE COUNT; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 71849093191     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20219     Document Type: Article

References (13)

1. Kotasek D, Shepherd KM, Sage RE, Dale BM, Norman JE, Charles P, Gregg A, Pillow A, Bolton A. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992;9:11-17.
2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97. (Pubitemid 26240110)
3. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988;28:1194-1198. (Pubitemid 18140273)
4. Nowrousian MR, Waschke S, Bojko P, Welt A, Schuett P, Ebeling P, Flasshove M, Moritz T, Schuette J, Seeber S. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients. Ann Oncol 2003;14:i29-i36. (Pubitemid 36701721)
5. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W. An analysis of engraftment kinetics as a function of the CD 34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-3969.
6. Alegre A, Tomás JF, Martínez-Chamorro C, Gil-Fernández JJ, Fernández-Villalta MJ, Arranz R, Díaz MA, Granda A, Bernardo MR, Escudero A, López-Lorenzo JL, Fernández-Ranãda JM. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs. G-CSF alone. Bone Marrow Transplant 1997;20:211-217. (Pubitemid 27361913)
7. Dolgopolov I, Andreeva L, Yankelevich M, Scheidze D, Siegel S, Mentkevich G. Delayed introduction of G-CSF after chemotherapy does not affect peripheral blood stem cell yield and engraftment kinetics in children with high-risk malignancies: retrospective study of 45 cases. Am J Hematol 2003;73:225-229. (Pubitemid 36898877)
8. Teshima T, Harada M, Takamatsu Y, Makino K, Taniguchi S, Inaba S, Kondo S, Tanaka T, Akashi K, Minamishima I. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant 1992;10:215-220.
9. Oki Y, Ogura M, Kato H, Kikuchi A, Taji H, Kagami Y, Oshiro A, Tsujimura A, Yamamoto K, Morishima Y. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Sci 2008;99:179-184. (Pubitemid 350239048)
10. Lonial S, Arellano M, Hutcherson D, Langston A, Flowers C, Heffner LT, Winton E, Jo Lechowicz M, Waller EK. Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. Leuk Lymphoma 2006;47:2155-2162. (Pubitemid 44650093)
11. D'Sa S, Yong K, Kyriakou C, Bhattacharya S, Peggs KS, Foulkes B, Watts MJ, Ings SJ, Ardeshna KM, Goldstone AH, Williams CD. Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects. Br J Haematol 2004;125:756-765. (Pubitemid 38813602)
12. Yankelevich M, Goodell MA, Kaplan J. Efficacy of delayed administration of post-chemotherapy granulocyte colony-stimulating factor: evidence from murine studies of bone marrow cell kinetics. Exp Hematol 2008;36:9-16. (Pubitemid 350266968)
13. Zaucha JM, Knopińska-Posłuszny W, Bieniaszewska M, Myśliwski A, Hellmann A. The effect of short G-CSF administration on the numbers and clonogenic efficiency of hematopoietic progenitor cells in bone marrow and peripheral blood of normal donors. Ann Transplant 2000;5:20-26.